ESMO MAP 2022 | Genomic evolution of NSCLC during the establishment of patient-derived xenograft models

Robert Hynds, PhD, UCL, London, UK, discusses an investigation into the genomic evolution of non-small cell lung cancer (NSCLC) during the establishment and propagation of patient-derived xenograft (PDX) models. Dr Hynds addresses the challenges of interpatient variability within NSCLC when developing PDX models. PDX models were developed from multiple regions of primary NSCLC from patients in lung TRACERx (NCT01888601) study to assess the fidelity of PDX models as a surrogate for the patients’ tumor. Due to associated challenges, PDX models were developed for approximately 50% of patients, however the explanation as to why PDX models cannot be developed from particular patients has yet to be elucidated, although tumor stage was found to be a correlate. The accuracy of the PDX models to represent the primary tumor from which it was derived was assessed, which demonstrated the PDX model could effectively represent the region of the tumor from which it was derived, but was ineffective at recapitulating the whole tumor in regard to tumor heterogeneity. Additionally, whether or not the PDX tumor models continue to evolve in the mouse was investigated. The full research paper can be viewed here: https://www.biorxiv.org/content/10.1101/2023.01.06.521078v1.full. This interview took place at the Molecular Analysis for Precision oncology (MAP) Congress 2022 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.